Emerging Strategies in the Treatment of Hodgkin Lymphoma

In this segment, “Emerging Strategies in the Treatment of Hodgkin Lymphoma”, Stephen Ansell, MD, PhD, and Craig Moskowitz, MD, discuss integrating newer therapies into practice.

The field of Hodgkin lymphoma is changing dramatically. In early-stage disease, combinations of chemotherapy with antibody-drug conjugates or anti–PD-1 agents have shown positive results. Integrating these agents into earlier lines of therapy requires assessing risk tolerance related to different strategies and presents challenges with treatment selection and sequencing with subsequent lines of treatment. The role of transplantation and the importance of clinical trials are also discussed.
Previous Article New and Emerging Agents in the Treatment of Diffuse Large B-Cell Lymphoma
Next Article Exciting Aspects in AML Therapies in 2021 and Beyond